This Article Full Text Full Text (PDF) All Versions of this Article: 42/2/184    most recent 01.HYP.0000082360.65547.7Cv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanner, F. C. Articles by Lüscher, T. F. Search for Related Content PubMed PubMed Citation Articles by Tanner, F. C. Articles by Lüscher, T. F. Pubmed/NCBI databases Medline Plus Health Information High Blood Pressure Related Collections Other hypertension Animal models of human disease Cell biology/structural biology Cell signalling/signal transduction Gene expression Smooth muscle proliferation and differentiation

(Hypertension. 2003;42:184.)
© 2003 American Heart Association, Inc.

Scientific Contributions

Different Cell Cycle Regulation of Vascular Smooth Muscle in Genetic Hypertension

Felix C. Tanner; Helen Greutert; Christine Barandier; Karin Frischknecht; Thomas F. Lüscher

From Cardiovascular Research, Physiology Institute, University Zürich-Irchel, and the Division of Cardiology, University Hospital, Zürich (F.C.T., H.G., K.F., T.F.L.); and the Physiology Institute, University of Fribourg (C.B.), Fribourg, Switzerland.

Correspondence to Felix C. Tanner, MD, Cardiovascular Research, Physiology Institute, University Zürich-Irchel, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland. E-mail felix.tanner{at}access.unizh.ch

Vascular smooth muscle cells (VSMC) from spontaneously hypertensive rats (SHR) proliferate faster than those from Wistar-Kyoto rats (WKY). Therefore regulation of cell cycle progression was examined in VSMC from both strains. Analysis of G1 progression was performed in VSMC synchronized by serum starvation. Double staining for propidium iodide and bromodeoxyuridine revealed that G1 progression was faster in SHR as compared with WKY. Indeed, 59±6% of VSMC from SHR but only 14±10% of those from WKY had left G1 phase after 24 hours of mitogenic stimulation. Moreover, 15±2% of SHR cells had already completed the cycle at this time point. Western blot analysis demonstrated that the level of cyclin D, cyclin E, and cyclin A was higher in SHR cells progressing through G1 phase, whereas expression of cyclin-dependent kinase 2 as well as the cyclin-dependent kinase inhibitors p21 and p27 were similar in the two groups. Consistent with a higher level of cyclins, the activity of cyclin-dependent kinase 2 was more pronounced in SHR cells. Analysis of G2 progression was performed in VSMC synchronized by treatment with aphidicolin and revealed an additional difference in cell cycle regulation between SHR and WKY. Indeed, the level of cell division cycle kinase 2 was higher in cells from SHR, whereas that of its catalytic partner cyclin B was similar. Consistent with this pattern of expression, the activity of cell division cycle kinase 2 was more pronounced in VSMC from SHR as compared with WKY. Thus, these data demonstrate that the different proliferation of VSMC from SHR and WKY is related to a different progression in G1 phase as the result of the expression of cyclin D, cyclin A, and cyclin E as well as a different progression in G2 phase caused by expression of cell division cycle kinase 2.

Key Words: rats, spontaneously hypertensive • muscle, smooth, vascular • hypertension, genetic • molecular biology

This article has been cited by other articles:

				R. Gros, Q. Ding, J. Chorazyczewski, J. Andrews, J. G. Pickering, R. A. Hegele, and R. D. Feldman The Impact of Blunted beta-Adrenergic Responsiveness on Growth Regulatory Pathways in Hypertension Mol. Pharmacol., January 1, 2006; 69(1): 317 - 327. [Abstract] [Full Text] [PDF]

				J. Steffel, R. A. Latini, A. Akhmedov, D. Zimmermann, P. Zimmerling, T. F. Luscher, and F. C. Tanner Rapamycin, but Not FK-506, Increases Endothelial Tissue Factor Expression: Implications for Drug-Eluting Stent Design Circulation, September 27, 2005; 112(13): 2002 - 2011. [Abstract] [Full Text] [PDF]